Would this be compelling enough data, especially w
Post# of 151830
(Total Views: 440)
Posted On: 04/07/2025 6:34:57 PM
Re: HouseofCards #151660
Quote:
Would this be compelling enough data, especially with our safety profile, to issue a conditional approval while we ran a confirmatory trial?
I would consider it unlikely when it consists of disparate trials. It should be more than enough for a phase 3.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼